The WHO said the group of experts would consider the evidence for liraglutide over the coming months.

世卫组织表示，专家小组将在未来几个月考虑利拉鲁肽的证据。

Novo Nordisk said in a statement it was not involved in the request to consider liraglutide for the WHO list.

诺和诺德公司在一份声明中表示，它没有提出考虑将利拉鲁肽列入世卫组织清单的请求。

Their request covers the active ingredient liraglutide, which is used in the obesity drug Saxenda.

他们请求将减肥药Saxenda中使用的活性成分利拉鲁肽纳入清单。

So far only three GLP-1 drugs have been approved to treat obese or overweight individuals: liraglutide and semaglutide, developed by Novo; and tirzepatide, made by Lilly.

到目前为止，只有三种GLP-1药物被批准用于治疗肥胖或超重个体：利拉鲁肽和索马鲁肽，由Novo开发;和 tirzepatide，由 Lilly 制造。